Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Asklepios Biopharmaceutical Inc. is currently managing 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. This level of activity indicates a robust prosecution phase for the company's intellectual property. The concentration in biotechnology suggests that the company's legal efforts are heavily invested in the complex technical and regulatory requirements of the pharmaceutical industry.
The workload is spread across 4 distinct examiners and 4 distinct art units. This distribution shows that each of the 4 pending office actions is being reviewed in a unique specialized environment by a different individual. This structure requires the company to navigate four separate prosecution paths, as each examiner may have different interpretations of the relevant biotechnology art and legal standards.
Noakes, Suzanne Marie is identified as the busiest examiner, with 1 pending office action. While this examiner has the highest count of pending actions for the company, they only handle one of the 4 total actions. This even distribution across the 4 distinct examiners means that no single individual has a dominant influence over the company's current pending applications, requiring a broad management strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (50%) |
| §112 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOAKES, SUZANNE MARIE | 1 | 73.3% | +18.2% |
| BRETZ, COREY LANE | 1 | 0.0% | +0.0% |
| PRONZATI, GINA | 1 | 66.7% | +45.9% |
| SPENCER, ANDREA LYNNE MORRIS | 1 | 22.2% | +35.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17913728 | FORSKOLIN-INDUCIBLE PROMOTERS AND HYPOXIA-INDUCIBLE PROMOTERS | BRETZ, COREY LANE | 29d overdue |
| 17919710 | REGULATORY NUCLEIC ACID SEQUENCES | NOAKES, SUZANNE MARIE | — |
| 17778175 | THERAPEUTIC ADENO-ASSOCIATED VIRUS COMPRISING LIVER-SPECIFIC PROMOTERS FOR TREATING POMPE DISEASE AND LYSOSOMAL DISORDERS | SPENCER, ANDREA LYNNE MORRIS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17919710 | REGULATORY NUCLEIC ACID SEQUENCES | NOAKES, SUZANNE MARIE | — |
| 17788679 | REGULATORY NUCLEIC ACID SEQUENCES | PRONZATI, GINA | — |
| 17778175 | THERAPEUTIC ADENO-ASSOCIATED VIRUS COMPRISING LIVER-SPECIFIC PROMOTERS FOR TREATING POMPE DISEASE AND LYSOSOMAL DISORDERS | SPENCER, ANDREA LYNNE MORRIS | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| 1635 | 1 |
| 1633 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17919710 | REGULATORY NUCLEIC ACID SEQUENCES | NOAKES, SUZANNE MARIE | 1656 | §101§112DP | Final Rejection | — | Pending | Oct 18, 2022 |
| 17913728 | FORSKOLIN-INDUCIBLE PROMOTERS AND HYPOXIA-INDUCIBLE PROMOTERS | BRETZ, COREY LANE | 1635 | §101§103§112Other | Final Rejection | 29d overdue | Pending | Sep 22, 2022 |
| 17788679 | REGULATORY NUCLEIC ACID SEQUENCES | PRONZATI, GINA | 1633 | §102§103DP | Non-Final OA | — | Pending | Jun 23, 2022 |
| 17778175 | THERAPEUTIC ADENO-ASSOCIATED VIRUS COMPRISING LIVER-SPECIFIC PROMOTERS FOR TREATING POMPE DISEASE AND LYSOSOMAL DISORDERS | SPENCER, ANDREA LYNNE MORRIS | 1631 | §112 | Final Rejection | — | Pending | May 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial